We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
151
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-140,000
Closed -$2.19M
SPY icon
152
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
– –
-3,500
Closed -$72.3M
SVRA icon
153
Savara
SVRA
$1.12B
– –
-19,641
Closed -$667K
THRM icon
154
Gentherm
THRM
$1.25B
– –
-34,550
Closed -$1.75M
TJX icon
155
TJX Companies
TJX
$174B
– –
-94,660
Closed -$3.31M
TVTX icon
156
Travere Therapeutics
TVTX
$5.2B
– –
-111,392
Closed -$2.67M
UNP icon
157
Union Pacific
UNP
$174B
– –
-17,489
Closed -$1.89M
XLV icon
158
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
– –
-59,853
Closed -$4.44M
LUMO
159
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-2,778
Closed -$1.37M
SRCL
160
DELISTED
Stericycle Inc
SRCL
– –
-14,500
Closed -$2.04M
NBSE
161
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-469
Closed -$476K
CBAY
162
DELISTED
Cymabay Therapeutics
CBAY
– –
-157,179
Closed -$1.09M
SPPI
163
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-50,000
Closed -$304K
AERI
164
DELISTED
Aerie Pharmaceuticals
AERI
– –
-90,000
Closed -$2.82M
ENDP
165
DELISTED
Endo International plc
ENDP
– –
-210,000
Closed -$18.8M
EPZM
166
DELISTED
Epizyme, Inc
EPZM
– –
-150,000
Closed -$2.82M
HSTO
167
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-1,100
Closed -$1.57M
ALXN
168
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-25,000
Closed -$4.33M
STML
169
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-80,957
Closed -$1.17M
GNMX
170
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-175,000
Closed -$1.41M
ACHN
171
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-65,538
Closed -$646K
INSY
172
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-200,000
Closed -$5.81M
KERX
173
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-230,000
Closed -$2.93M
JUNO
174
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-15,000
Closed -$910K
OCRX
175
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-321,254
Closed -$1.51M
4 5 6
7
8

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.